If you have been reading about tesamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-18. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
* where the cluster needs a third body to get collisionally stabilized. The main advantage of using NH4+ reagent ions is that fragmentation of analytes upon chemical ionization is strongly suppressed, leading to straightforward mass spectra even for complex mixtures. The reason why during the first 20 years after the invention of PTR-MS NH4+ reagent ions have only been used in a very limited number of studies is most probably because the NH4+ production required toxic and corrosive ammonia as a source gas. This led to problems with handling the instrument and its exhaust gas, as well as to increased wear of vacuum components. In 2017 a patent application was submitted where the inventors introduced a novel method of NH4+ production without the need of any form of ammonia. In this method N2 and water vapor are introduced into the hollow cathode ion source and by adjusting electric fields and pressures NH4+ can be produced at the same or even higher purity levels than H3O+. It is expected that this invention, which eliminates the problems connected to the use of NH4+ so far, will lead to a widespread use of NH4+ reagent ions in the near future.
The vacuum flask was designed and invented by Scottish scientist James Dewar in 1892 as a result of his research in the field of cryogenics and is sometimes called a Dewar flask in his honour. While performing experiments in determining the specific heat of the element palladium, Dewar made a brass chamber that he enclosed in another chamber to keep the palladium at its desired temperature. He evacuated the air between the two chambers, creating a partial vacuum to keep the temperature of the contents stable. Dewar refused to patent his invention; this allowed others to develop the flask using new materials such as glass and aluminium, and it became a significant tool for chemical experiments and also a common household item.
On May 26, 2016, Green Berets supported about 80 soldiers of the Afghan 3rd Special Operations Battalion whose mission was to clear insurgents from Elbak, Kandahar province. The goal was to clear the road from Kandahar through Elbak to Tarin Kowt and allow an 800-man Afghan army convoy to deliver troops and supplies to Tarin Kowt. Green Berets called in three airstrikes by U.S. drones on Taliban insurgents near the landing zone, killing seven and wounding others. The mission had mixed results. The Taliban reoccupied the area and the convoy barely made any progress, however the operation interrupted the Taliban's nightly routine of bomb-planting. A week later, the Afghan commandos removed 18 booby-trap bombs from the road and made their way slowly through Elbak and further north. On August 23, a US soldier from A Company, 3rd battalion, 1st SFG, was killed by an IED while another was wounded along with six Afghans during a foot patrol near Lashkar Gah, Helmand Province. On October 4, 2016, a US soldier from B Company, 2nd Battalion, 10th SFG was killed by a roadside bomb blast in Achin, Nangarhar province. He was on a patrol with Afghan forces during an operation against ISIL-KP militants. This marked the first time a U.S. serviceman was killed in combat against IS militants in the country. On October 17, DEA agents, supported by a US Army Green Beret A-team and Afghan counter-narcotic units conducted a warranted search in a remote village in Farah province.
Sources: en.wikipedia.org
Patients are also advised to focus on dehydration and go to the hospital in case of frequent vomiting. It's essential to emphasize that insulin should never be discontinued, even if there is no intake of food or fluids. Patients' education and awareness of managing a sick day is a key element, as recognizing symptoms, and knowing when to contact a healthcare provider. This education significantly contributes to reducing the occurrence of DKA.
=== Organic and inorganic synthesis === Due to its explosion hazard, sodium azide is of only limited value in industrial-scale organic synthesis. In the laboratory, it is used to introduce the azide functional group by displacement of halides. The azide functional group can thereafter be converted to an amine by reduction with either SnCl2 in ethanol or lithium aluminium hydride or a tertiary phosphine, such as triphenylphosphine in the Staudinger reaction, with Raney nickel or with hydrogen sulfide in pyridine. Oseltamivir, an antiviral medication, is currently produced in commercial scale by a method which utilizes sodium azide. Sodium azide is a versatile precursor to other inorganic azide compounds, e.g., lead azide and silver azide, which are used in detonators as primary explosives. These azides are significantly more sensitive to premature detonation than sodium azide and thus have limited applications. Lead and silver azide can be made via double displacement reaction with sodium azide and their respective nitrate (most commonly) or acetate salts. Sodium azide also can react with the chloride salts of certain alkaline earth metals in aqueous solution, such as barium chloride or strontium chloride to respectively produce barium azide and strontium azide, which are also relatively sensitive primarily explosive materials. These azides can be recovered from solution through careful desiccation.
== Adverse effects == Various adverse effects may occur according to the pre-workout product and dose of supplement consumed. Some potential side effects of taking pre-workout could include nausea and skin irritation. One ingredient that causes this to happen is beta-alanine. Beta-alanine is commonly included in pre-workouts. It is known to temporarily create an itching sensation on skin. This sensation is harmless. It typically occurs shortly after consumption and is dose dependent. Other adverse effects have been shown to arise when the product contains ingredients such as synephrine and caffeine. Synephrine is often used as a weight loss supplement and commonly found in pre-workout. Synephrine has been found to cause heart problems and other cardiovascular issues. Caffeine is also a common ingredient found in pre-workout which may cause an increase in blood pressure. Another issue that may arise is a higher risk in cardiac and liver related diseases due to the high concentration of caffeine in these types of products.
Sources: en.wikipedia.org
=== 2009-2013: Lineup changes, Teške Boje === By the end of 2009, Kilmister, Domaćinović, Tibljaš and Blažević left the band due to personal differences with Bare. This left Bare as the only remaining original member of Majke. He and Čalić assembled a new lineup consisting of bassist Mario Rašić, who previously played with Bare in his backing band Plaćenici; Gatuzo guitarist Damir Trkulja - Šiljo, drummer Damir Šomen and keyboardist Viktor Lipić. This lineup recorded the band's sixth studio album, "Teške Boje", which was released in 2011. On this album, the band displayed a much darker and more aggressive style of blues rock, with psychedelic elements mixed in as well. The title track was a hit, with some critics even calling it the "best Croatian rock song of the last 20 years", and a music video was filmed for it. Other staples from the album included "Pozovi Me U Noć" and "Depresija". In 2012, the album won several Porin awards for song of the year, best rock album, and best music video of the year. Soon afterwards, Šiljo left the band due to personal differences with Bare and was replaced by ex-Pips, Chips i Videoclips guitarist Alen Kraljić, who also played with Bare as a member of Plaćenici. In 2013, the band released the live album "Majke U Tvornici", which was recorded six years ago at the Tvornica Kulture venue. By the end of the year, Zoran Čalić left the band once again. He went on to form a new band called Zoran Čalić Bend.
Commercial nuclear fission reactors are operated in the otherwise self-extinguishing prompt subcritical state. Certain fission products decay over seconds to minutes, producing additional delayed neutrons crucial to sustaining criticality. An example is bromine-87 with a half-life of about a minute. Operating in this delayed critical state, power changes slowly enough to permit human and automatic control. Analogous to fire dampers varying the movement of wood embers towards new fuel, control rods are moved as the nuclear fuel burns up over time. In a nuclear power reactor, the main sources of radioactivity are fission products along with actinides and activation products. Fission products are most of the radioactivity for the first several hundred years, while actinides dominate roughly 103 to 105 years after fuel use. Most fission products are retained near their points of production. They are important to reactor operation not only because some contribute delayed neutrons useful for reactor control, but some are neutron poisons that inhibit the nuclear reaction. Buildup of neutron poisons is a key to how long a given fuel element can be kept in the reactor. Fission product decay also generates heat that continues even after the reactor has been shut down and fission stopped. This decay heat requires removal after shutdown; loss of this cooling damaged the reactors at Three Mile Island and Fukushima. If the fuel cladding around the fuel develops holes, fission products can leak into the primary coolant.
=== Type 2 diabetes === In the BEGIN Basal-Bolus Type 2 trial, insulin degludec was studied as an alternative to insulin glargine in participants with type 2 diabetes. 995 participants were randomized to receive either insulin degludec (n=755) or insulin glargine (n=251), in addition to either mealtime insulin aspart, metformin, and/or pioglitazone. Participants in this trial had an average HbA1c of 8.3–8.4%, and 49–50% were on a regimen consisting of basal-bolus insulin plus oral antidiabetic medications. After 52 weeks, insulin degludec was found to be noninferior to insulin glargine, providing a similar HbA1c lowering effect (−1.10 vs. −1.18%). Overall rates of hypoglycemia were significantly lower with insulin degludec (11.09 vs. 13.63%/yr, p=0.0359), including cases of nocturnal hypoglycemia (1.39 vs. 1.84%/yr, p=0.0399).
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.